Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15,

Slides:

Advertisements

Similar presentations

Workshop on SPS Coordination 17 October 2011 Codex Alimentarius Commission Standard-setting Procedures Selma H. Doyran Joint FAO/WHO Food Standards Programme.

Advertisements

Presented by Bo Olsson (AstraZeneca)

Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

USP and Dissolution Testing Advisory Committee for Pharmaceutical Sciences 2 May 2005 Will Brown Staff Liaison to the Biopharmaceutics Expert Committee.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

Best Practices for OINDP Pharmaceutical Development Programs Leachables and Extractables PQRI Leachables & Extractables Working Group PQRI Training Course.

CFSAN’s Peer Review for Risk Assessments Robert L. Buchanan, Sherri Dennis, and Marianne Miliotis.

Lessons Learned in Initiating and Conducting Risk Assessments within a Risk Analysis Framework: A FDA/CFSAN Approach Robert Buchanan DHHS Food and Drug.

Rapid Microbiology Methods A Regulatory Viewpoint Bryan S. Riley, Ph.D. U.S. Food and Drug Administration Center for Drug Evaluation and Research Office.

Health Canada/FDA Favorite Links Lynda Paleshnuik Training workshop: Assessment of Interchangeable Multisource Medicines, Kenya, August 2009.

Implementation of Quality-by-Design: ONDQA Initiatives Advisory Committee for Pharmaceutical Science October 5, 2006 Chi-wan Chen, Ph.D. Deputy Director.

Office of New Drug Chemistry, OPS, CDER, Food and Drug Administration Establishing Dissolution Specification Current CMC Practice Vibhakar Shah, Ph.D.

Slide: 1 27 th CEOS Plenary |Montréal | November 2013 Agenda Item: 15 Chu ISHIDA(JAXA) on behalf of Rick Lawford, GEO Water CoP leader GEO Water.

Assessing Quality-by-Design A CMC Review Perspective

PK and PD Studies for Systemic Exposure of Locally Acting Drugs Industry View Lester I. Harrison, PhD Division Scientist 3m Pharmaceuticals.

Individual Bioequivalence Lawrence J. Lesko, Ph.D. Director Office of Clinical Pharmacology and Biopharmaceutics Advisory Committee for Pharmaceutical.

1 ACPS November 15, Update Nancy B. Sager, Associate Director Office of Pharmaceutical Science Center for Drug Evaluation & Research Food and.

FDA Nasal BA/BE Guidance Overview

Venkata Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.

1 Process to Address Specifications for Delivered Dose Uniformity of Inhaled and Nasal Drug Products Presented by Robert O’Neill, Ph.D. Chair ACPS Working.

Nonclinical Studies Subcommittee Advisory Committee for Pharmaceutical Science CMC Issues for Screening INDs Eric B. Sheinin, Ph.D. Acting Deputy Director.

ITFG/IPAC Collaboration CMC Specifications Technical Team ITFG/IPAC TECHNICAL TEAM: CMC SPECIFICATIONS Presented by: Bo Olsson, PhD 26 April 2000 Rockville,

Physiologists & the FDA Kevin J. Greenlees, Ph.D., DABT Senior Advisor for Science & Policy Office of New Animal Drug Evaluation FDA Center for Veterinary.

Establishing Drug release/Dissolution Specifications – QBD Approach Moheb M. Nasr, Ph.D. Office of New Drug Quality Assessment (ONDQA), OPS, CDER Advisory.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Welcome and Introduction to the Meeting.

1 The June 1999 Draft BA/BE Guidance for Nasal Aerosols and Nasal Sprays: History, Recommendations and Local Delivery Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA.

2015 MBSW1 Quality Assurance Test of Delivered Dose Uniformity of Multi-dose Spray and Inhalation Drug Products Drs. Yi Tsong 1, Xiaoyu (Cassie) Dong*

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Secretary’s Advisory Committee on Human Subjects Protections (SACHRP) Summary of Responses on: Advanced Notice of Proposed Rulemaking (ANPRM) on Holding.

1 Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July , 2008 Classification of Orally Disintegrating Tablets Frank O. Holcombe,

Implementing GRADE in Guideline Development: Real-World Experiences NIAID Guidelines for the Diagnosis and Management of Food Allergy Dr. Matthew Fenton.

NDAC December 14, Nonprescription Drugs Advisory Committee Meeting Silver Spring, Maryland December 14, 2007 Mary S. Robinson, MS Division of Nonprescription.

Ozone National Air Quality Standard Review WESTAR Fall Business Meeting Boise, Idaho September 2006.

Parametric Tolerance Interval Test for Delivered Dose Uniformity (DDU) Working Group Update Moheb M. Nasr, Ph.D. Office of New Quality Assessment (ONDQA,

Bioequivalence Studies and Other Recommendations for Orally Inhaled and Nasal Drug Products: Work of the ITFG/IPAC-RS Collaboration Presented by Cynthia.

Waiver of In Vivo Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System Ajaz S. Hussain,

Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.

1 ORALLY INHALED AND NASAL DRUG PRODUCTS FOR LOCAL ACTION Current FDA BA/BE Background and Issues Wallace P. Adams, Ph.D. OPS/CDER/FDA OINDP Subcommittee.

Overview of FDA's Regulatory Framework for PET Drugs

Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.

Developing Consensus Principles and Standards for Evaluating Global and Regional Partnership Programs (GRPPs) Progress Report to the Fifth Meeting of the.

COMPARABILITY PROTOCOLUPDATE ADVISORY COMMITTEE FOR PHARMACEUTICAL SCIENCE Manufacturing Subcommittee July 20-21, 2004 Stephen Moore, Ph.D. Chemistry Team.

Guidance Update: Average, Population, and Individual Approaches to Establishing Bioequivalence Mei-Ling Chen, Ph.D. Associate Director Office of Pharmaceutical.

1 Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meeting Detection of Porcine circovirus (PCV) and PCV DNA Sequences in U.S. Licensed.

1 Subcommittee Report: Orally Inhaled and Nasal Drug Products (OINDP) Wallace P. Adams, Ph.D. OPS/CDER/FDA Advisory Committee for Pharmaceutical Science.

Dermatopharmacokinetics (DPK)

February 2, 2004 Pediatric Drug Development: A Decade of Progress: Susan K. Cummins, MD, MPH Medical Team Leader Division of Pediatric Drug Development.

1 Dose Content Uniformity for Aerosol Products Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 13 March 2003 Rockville, MD.

1 PTIT for DCU of OINDP: Approaches to Resolution of Identified Issues Wallace P. Adams, Ph.D. OPS/IO Advisory Committee for Pharmaceutical Science 21.

ITFG/IPAC Collaboration Introduction OVERVIEW OF ITFG/IPAC COLLABORATION Presented by: Harris Cummings, PhD 26 April 2000 Rockville, MD.

ITFG/IPAC Collaboration BA/BE Technical Team ITFG/IPAC TECHNICAL TEAM: BA/BE IN VITRO AND IN VIVO TESTS Presented by: Stephen Farr, PhD 26 April 2000 Rockville,

ITFG/IPAC Collaboration CMC Supplier Quality Control Technical Team ITFG/IPAC TECHNICAL TEAM: SUPPLIER QUALITY CONTROL (QUALIFICATION) Presented by: Gordon.

Bioequivalence Criteria Research Plan Stella G. Machado, Ph.D. Office of Biostatistics and the Replicate Design Technical Committee Advisory Committee.

Lawrence X. Yu, Ph.D. Director for Science Office of Generic Drugs, OPS, CDER, FDA ACPS Meeting, ACPS Meeting, Oct. 22, 2003 Office of Generic Drugs Research.

FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.

Orally Inhaled and Nasal Drug Products Subcommittee Introduction and Objectives Eric B. Sheinin Deputy Director Office of Pharmaceutical Science Center.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.

USP: Water for Pharmaceutical Purposes NCSLI – Metrological Traceability in Pure Water Testing August 22, 2011 Antonio Hernandez-Cardoso Senior Scientific.

ITFG/IPAC Collaboration CMC Leachables and Extractables Technical Team ITFG/IPAC TECHNICAL TEAM: CMC LEACHABLES AND EXTRACTABLES Presented by: Kaushik.

3M Drug Delivery Systems 3 Introduction The headspace of pressurized metered dose inhaler (MDI) canisters is filled by the vapor of volatile components,

Ajaz S. Hussain, Ph.D. Office of Pharmaceutical Sciences CDER, FDA October 21, 2003 Dose Content Uniformity: Parametric Tolerance Interval Approach.

Office of Pharmaceutical Science OPS Center for Drug Evaluation and Research CDER FDA Food and Drug Administration HHS Health and Human Services 1 Advisory.

Guidance Development Merton V. Smith, Ph.D., J.D. Director International Programs and Product Standards Center for Veterinary Medicine, FDA.

Parametric Tolerance Interval (PTI) Test for Delivered Dose Uniformity (DDU) for Orally Inhaled and Nasal Drug Products (OINDP) Michael Golden On behalf.

An Assessment of IPAC-RS’ Proposal Walter W. Hauck, Ph.D. Biostatistics Section Division of Clinical Pharmacology Thomas Jefferson University Philadelphia,

USP and Dissolution Testing

USP and Dissolution Testing

EU Water Framework Directive

Presentation transcript:

Orally Inhaled and Nasal Drug Products (OINDP) Subcommittee Report to the Advisory Committee for Pharmaceutical Sciences Rockville, Maryland November 15, 2000 Dose Content Uniformity Issues Guirag Poochikian, Ph.D. Chemistry Team Leader Division of Pulmonary and Allergy Drug products Center For Drug Evaluation and Research Food and Drug Administration

Outline Background Questions Summary of Comments

Published OINDP Draft CMC Guidances (Under Revision) Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug products Chemistry, Manufacturing, and Controls Documentation Nasal Spray and Inhalation Solution, Suspension, and Spray Drug products Chemistry, Manufacturing, and Controls Documentation

Activities Since Publication of the OINDP Draft Guidances Public Comments on MDI and DPI Drug Products Guidance (March 1999) AAPS/FDA/USP Workshop (June 3-4, 1999) Public Comments on Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products Guidance (September 1999) OINDP Expert Panel (November 1999) OINDP Subcommittee Meeting (April 2000) OPS Advisory Committee (November 2000)

Dose Content Uniformity Dose uniformity among units within a batch (Inter-unit/Intra-batch) Dose-to-Dose uniformity within a unit/container (Intra-unit)

Questions to Subcommittee A.Should there be a single content uniformity standard for all orally inhaled and nasal drug products (OINDPs)? B.Should the FDA continue development of the proposed statistical approach to evaluating content uniformity?

Summary of Comments on Question A Data are needed before the question can be answered. A single C.U. standard would be desirable. Last decade D.P.s AP under FDA guidance criteria. Multiple standards may be the best approach. Existing D.P.s may be grandfathered until phase-out. C.U. considered in context of in vitro/in vivo assessments. Lack of standardization unfair to clinicians and public.

Questions to Subcommittee A.Should there be a single content uniformity standard for all orally inhaled and nasal drug products (OINDPs)? B.Should FDA continue development of the proposed statistical approach to evaluating content uniformity?

Summary of Comments on Question B Yes. FDA should continue development of the proposed statistical approach by Dr. Hauck. Data from existing products would enable the parametric statistical approach to move forward. Other statistical approaches may be considered. With Dr. Hauck’s statistical approach, the Agency sets the allowable consumer risk, and the producer determines its own risk. One approach would be to use the properties of reference products to help determine criteria.